The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
Open Access
- 12 September 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 131 (3), 752-759
- https://doi.org/10.1002/ijc.26421
Abstract
Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%) among 258 patients who used metformin, compared with 136 total deaths (40.4%) and 104 CRC-specific deaths (30.9%) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476–0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95% CI 0.45–0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.Keywords
This publication has 31 references indexed in Scilit:
- Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organsThe Esophagus, 2010
- Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinaseMolecular Carcinogenesis, 2010
- Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic CancerClinical Cancer Research, 2010
- Insulin resistance and hyperinsulinaemia in the development and progression of cancerClinical Science, 2009
- Metformin Associated With Lower Cancer Mortality in Type 2 DiabetesDiabetes Care, 2009
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong RemissionCancer Research, 2009
- Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-AnalysisDigestive Diseases and Sciences, 2009
- Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer modelBreast Cancer Research and Treatment, 2008
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerThe Lancet, 2000